ENGENEIC
EnGeneIC is a bioscience company, develops and commercializes novel concepts in the targeted delivery of chemotherapeutics for cancer drugs in-vivo. The companyโs drug/siRNA delivery vehicles offer a range of choices for optimizing the delivery of clinically meaningful drug and siRNA doses to target cancer cells in-vivo. It serves customers in Australia, Singapore, Japan, and India. The company was incorporated in 2000 and is based in Lane Cove West, Australia.
ENGENEIC
Industry:
Biotechnology Life Science Therapeutics
Founded:
2000-01-01
Address:
Sydney, New South Wales, Australia
Country:
Australia
Website Url:
http://www.engeneic.com
Total Employee:
11+
Status:
Active
Contact:
+61294205844
Total Funding:
16.98 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome Domain Not Resolving
Current Employees Featured
Founder
Investors List
Foley Ventures
Foley Ventures investment in Series B - EnGeneIC
Shepherd Kaplan Krochuk
Shepherd Kaplan Krochuk investment in Series B - EnGeneIC
Official Site Inspections
http://www.engeneic.com
- Host name: 66.0.153.160.host.secureserver.net
- IP address: 160.153.0.66
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "EnGeneIC"
EnGeneIC - Crunchbase Company Profile & Funding
EnGeneIC is a bioscience company, develops and commercializes novel concepts in the targeted delivery of chemotherapeutics for cancer drugs in โฆSee details»
EnGeneIC - LinkedIn
EnGeneIC | 2,231 followers on LinkedIn. First-in-class cyto-immunotherapy platform targeting the tumour directly and leveraging the patient's immune system | EngeneIC is a biopharmaceutical ...See details»
EnGeneIC 2025 Company Profile: Valuation, Funding & Investors
EnGeneIC General Information Description. Developer of a clinical-stage biopharmaceutical company designed to target the delivery of chemotherapeutics and functional nucleic acids in โฆSee details»
EnGeneIC - 2025 Company Profile, Funding & Competitors - Tracxn
EnGeneIC is a series B company based in Lane Cove (Australia), founded in 2000 by Himanshu Brahmbhatt and Jennifer MacDiarmid. It operates as a Developer of technology for delivery of โฆSee details»
EnGeneIC Company Profile - Office Locations, Competitors ... - Craft
EnGeneIC has 5 employees across 2 locations and $21.1 m in total funding,. See insights on EnGeneIC including office locations, competitors, revenue, financials, executives, subsidiaries โฆSee details»
EnGeneIC - The Org
EnGeneIC develops and commercializes the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells.See details»
Tech start-ups: cancer biotech EnGeneIC raising $20 million after ...
Nov 13, 2022 Sydney-based biotech EnGeneIC is tapping investors to raise $20 million in bridging funding to buy time until the IPO market reopens and the company can undertake a โฆSee details»
EnGeneIC - Contacts, Employees, Board Members, Advisors
EnGeneIC develops and commercializes the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells. ... Experience the new Crunchbase, powered by AI โฆSee details»
EnGeneIC - Leadership Team - The Org
EnGeneIC. Teams; Leadership Team; Leadership Team. About. EnGeneIC's Leadership Team includes Scott Pattison and 9 others. Team members. Bill Harris. CFO. David Seaton. COO. โฆSee details»
Australian Biotech EnGeneIC Strikes Landmark Deal with Major US โฆ
EnGeneICโs patented EDVโข (EnGeneIC Dream Vector) nanocell technology also targets and effectively kills cancer cells with minimal toxicity, while stimulating an anti-tumour im-mune โฆSee details»
EnGeneIC Selects Global CDMO BioCina to Advance Their Ground โฆ
Sep 24, 2024 EnGeneIC is a clinical-stage biopharmaceutical company focused on advancing its proprietary EDVโข (EnGeneIC Dream Vector) nanocell technology for oncology and โฆSee details»
EnGeneIC Selects Global CDMO BioCina to Advance Their Ground โฆ
Sep 24, 2024 BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with drug developer โฆSee details»
Is EnGeneIC listed on the ASX? - The Motley Fool Australia
Joint EnGeneIC CEOs, Dr Himanshu Brahmbhatt and Dr Jennifer MacDiarmid, said: "We believe this collaboration will result in an effective vaccine, particularly against mutants of concern, โฆSee details»
EnGeneIC Pty Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Jan 23, 2025 ADELAIDE, South Australia, Sept. 24, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), โฆSee details»
EnGeneIC Pty Ltd. (EnGeneIC Pty Ltd.) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ้ช_ โฆ
ADELAIDE, South Australia, Sept. 24, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a โฆSee details»
EnGeneIC - Crunchbase Company Profile & Funding
EnGeneIC develops and commercializes the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells.See details»
EnGeneIC granted FDA ?Fast-Track? Designation for Novel Armed โฆ
Dec 8, 2023 EnGeneIC contact: Dr. Jennifer MacDiarmid Joint-CEO & Director & EDV technology co-inventor Email: [email protected] Cell phone: +61-407-953-170; โฆSee details»
Distinguished Oncologist, Professor Daniel Von Hoff joins the ...
Oct 1, 2024 EnGeneIC is a clinical-stage biopharmaceutical company focused on advancing its proprietary EDV (EnGeneIC Dream Vector) nanocell technology for oncology and infectious โฆSee details»
EnGeneIC and Singapore Institute of Advanced Medicine โฆ
Jun 7, 2024 SYDNEY, Australia, June 06, 2024 (GLOBE NEWSWIRE) -- EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted โฆSee details»
EnGeneIC Chooses BioCina as CDMO for Cancer Treatment
Sep 30, 2024 ADELAIDE, South Australia, Sept. 24, 2024 โ BioCina Pty Ltd., an international biologics Contract Development and Manufacturing Organization (CDMO), has announced a โฆSee details»